​Focus on cancer immunotherapy

Nature Reviews Immunology presents a themed Focus issue on the hot topics in immunotherapy research for tumour targeting.


Cancer immunotherapy – the targeting or use of immune system components to kill tumour cells – can take many forms, including antibodies, vaccines and T cells.

This Focus issue from Nature Reviews Immunology features three Review articles that highlight some of the most promising recent developments in this field: the use of checkpoint inhibitors for molecules such as PD1; the drive towards increased personalization of tumour vaccines; and the use of vaccines for prevention as well as cure.

In addition, three Opinion articles discuss how the local tumour microenvironment can be manipulated to improve the efficacy of immunotherapy, by normalizing the tumour vasculature, through local immunomodulation using synthetic, scaffold-based immune niches, and by targeting tumour glycosylation.

Read all the articles here: https://www.nature.com/collections/nrifocus-cancerimmunotherapy

Kirsty Minton

Senior Editor, Nature Research

I am Senior Editor at Nature Reviews Immunology. I studied at Cambridge University, gaining a triple first in Natural Sciences, where I specialized in cellular immunology and pathology. Since leaving Cambridge, I have focused on science communication, and joined Nature Reviews in 2002. I have been a Senior Editor for Nature Reviews Immunology since 2005.